JP2010539981A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539981A5 JP2010539981A5 JP2010528054A JP2010528054A JP2010539981A5 JP 2010539981 A5 JP2010539981 A5 JP 2010539981A5 JP 2010528054 A JP2010528054 A JP 2010528054A JP 2010528054 A JP2010528054 A JP 2010528054A JP 2010539981 A5 JP2010539981 A5 JP 2010539981A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- variable region
- seq
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 25
- 102000003735 Mesothelin Human genes 0.000 claims description 18
- 108090000015 Mesothelin Proteins 0.000 claims description 18
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 206010027406 Mesothelioma Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101710112752 Cytotoxin Proteins 0.000 claims description 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 7
- 239000002619 cytotoxin Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000012010 growth Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 6
- 230000002357 endometrial effect Effects 0.000 claims description 6
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 6
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 5
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims description 5
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 5
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims description 5
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims description 5
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 5
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000030427 mucinous ovarian cancer Diseases 0.000 claims description 5
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 5
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 101150000931 L6 gene Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 3
- 108010008629 CA-125 Antigen Proteins 0.000 claims description 2
- 102000007269 CA-125 Antigen Human genes 0.000 claims description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97662607P | 2007-10-01 | 2007-10-01 | |
| US60/976,626 | 2007-10-01 | ||
| US99169207P | 2007-11-30 | 2007-11-30 | |
| US60/991,692 | 2007-11-30 | ||
| US7739708P | 2008-07-01 | 2008-07-01 | |
| US61/077,397 | 2008-07-01 | ||
| PCT/US2008/078123 WO2009045957A1 (en) | 2007-10-01 | 2008-09-29 | Human antibodies that bind mesothelin, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539981A JP2010539981A (ja) | 2010-12-24 |
| JP2010539981A5 true JP2010539981A5 (enExample) | 2011-08-25 |
| JP5535074B2 JP5535074B2 (ja) | 2014-07-02 |
Family
ID=40526631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528054A Expired - Fee Related JP5535074B2 (ja) | 2007-10-01 | 2008-09-29 | メソテリンに結合するヒト抗体およびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US8268970B2 (enExample) |
| EP (1) | EP2195017B1 (enExample) |
| JP (1) | JP5535074B2 (enExample) |
| KR (2) | KR101554753B1 (enExample) |
| CN (1) | CN101951946B (enExample) |
| AR (1) | AR068590A1 (enExample) |
| AU (1) | AU2008308956B2 (enExample) |
| BR (1) | BRPI0816014A8 (enExample) |
| CA (1) | CA2700860C (enExample) |
| CL (1) | CL2008002923A1 (enExample) |
| CO (1) | CO6300960A2 (enExample) |
| CY (1) | CY1116036T1 (enExample) |
| DK (1) | DK2195017T3 (enExample) |
| EA (1) | EA018396B1 (enExample) |
| ES (1) | ES2526355T3 (enExample) |
| HR (1) | HRP20150074T1 (enExample) |
| IL (2) | IL204615A (enExample) |
| MX (1) | MX2010003581A (enExample) |
| NZ (1) | NZ584633A (enExample) |
| PL (1) | PL2195017T3 (enExample) |
| PT (1) | PT2195017E (enExample) |
| RS (1) | RS53760B1 (enExample) |
| SI (1) | SI2195017T1 (enExample) |
| TW (1) | TWI446922B (enExample) |
| WO (1) | WO2009045957A1 (enExample) |
| ZA (1) | ZA201002313B (enExample) |
Families Citing this family (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| SI2195017T1 (sl) * | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| HUE027358T2 (en) * | 2007-11-26 | 2016-09-28 | Bayer Ip Gmbh | Anti-mesothelin antibodies and their applications |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| PE20170917A1 (es) * | 2010-12-20 | 2017-07-12 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| EP3501546A3 (de) * | 2011-04-21 | 2019-09-18 | Seattle Genetics, Inc. | Cystein-wirkstoff konjugate und ihre verwendung |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| SMT201700137T1 (it) | 2012-02-13 | 2017-05-08 | Bristol Myers Squibb Co | Composti di endiini, loro coniugati, e loro usi e metodi |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014031476A1 (en) * | 2012-08-21 | 2014-02-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin domain-specific monoclonal antibodies and use thereof |
| WO2014052064A1 (en) * | 2012-09-27 | 2014-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
| LT2956173T (lt) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulizino junginiai, gavimo ir panaudojimo būdai |
| US10233249B2 (en) | 2013-03-19 | 2019-03-19 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| KR20160068738A (ko) | 2013-08-14 | 2016-06-15 | 윌리엄 마쉬 라이스 유니버시티 | 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도 |
| CN103819559B (zh) * | 2013-12-10 | 2016-02-24 | 中国科学院武汉病毒研究所 | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 |
| CA2931684C (en) * | 2013-12-19 | 2024-02-20 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| AU2015271709B2 (en) | 2014-06-06 | 2020-11-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| EP3151854B1 (en) | 2014-06-06 | 2020-02-26 | Memorial Sloan Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
| PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| MY187045A (en) | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
| KR20170102981A (ko) | 2015-01-14 | 2017-09-12 | 브리스톨-마이어스 스큅 컴퍼니 | 헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법 |
| MX2017009145A (es) | 2015-01-14 | 2017-11-22 | Bristol Myers Squibb Co | Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso. |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| ES2736106T3 (es) | 2015-03-10 | 2019-12-26 | Bristol Myers Squibb Co | Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos |
| MY188749A (en) | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| KR20180055824A (ko) * | 2015-08-21 | 2018-05-25 | 카르스젠 테라퓨틱스 리미티드 | 항 메소텔린 완전 인간 항체 및 메소텔린을 타겟팅하는 면역효과 세포 |
| KR101782487B1 (ko) * | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| CA3005855A1 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| US20180362619A1 (en) | 2015-12-21 | 2018-12-20 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| BR112018013074A2 (en) | 2015-12-30 | 2018-12-11 | Novartis Ag | immune effector cell therapies with enhanced efficacy |
| CA3016187A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3443096B1 (en) | 2016-04-15 | 2023-03-01 | Novartis AG | Compositions and methods for selective expression of chimeric antigen receptors |
| EP3448421B1 (en) * | 2016-04-29 | 2021-11-03 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| JP2019518013A (ja) | 2016-05-10 | 2019-06-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 安定性が向上したツブリシン類似体の抗体薬物結合体 |
| IL292302B2 (en) | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| ES2902179T3 (es) | 2016-08-19 | 2022-03-25 | Bristol Myers Squibb Co | Compuestos de seco-ciclopropapirroloindol, conjugados de anticuerpo-fármaco de los mismos y métodos de elaboración y uso |
| US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
| WO2018094282A1 (en) * | 2016-11-18 | 2018-05-24 | The Regents Of The University Of California | Engineered antibodies and uses thereof |
| IL324632A (en) | 2016-12-01 | 2026-01-01 | Regeneron Pharma | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| CN110300601B (zh) | 2017-02-08 | 2024-01-05 | Adc治疗有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| EA201991720A1 (ru) | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| WO2018183928A1 (en) | 2017-03-31 | 2018-10-04 | Bristol-Myers Squibb Company | Methods of treating tumor |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| US20200299400A1 (en) | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| WO2019075468A1 (en) | 2017-10-15 | 2019-04-18 | Bristol-Myers Squibb Company | TUMOR TREATMENT METHODS |
| KR101966362B1 (ko) | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| WO2019133639A2 (en) * | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Human antibodies that bind and are internalized by mesothelioma and other cancer cells |
| CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| JP2021521182A (ja) | 2018-04-12 | 2021-08-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療 |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| SG11202011739SA (en) | 2018-05-29 | 2020-12-30 | Bristol Myers Squibb Co | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| EP3807321A4 (en) * | 2018-06-18 | 2022-03-02 | Anwita Biosciences, Inc. | ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF |
| US11020490B2 (en) | 2018-06-22 | 2021-06-01 | Bristol-Myers Squibb Company | Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN110746508B (zh) * | 2018-07-23 | 2023-04-14 | 上海细胞治疗集团有限公司 | 特异性结合间皮素的单克隆抗体及嵌合抗原受体 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| JP2022513653A (ja) | 2018-11-28 | 2022-02-09 | ブリストル－マイヤーズ スクイブ カンパニー | 修飾された重鎖定常領域を含む抗体 |
| KR102861586B1 (ko) | 2018-11-30 | 2025-09-17 | 브리스톨-마이어스 스큅 컴퍼니 | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 |
| JP7514836B2 (ja) | 2018-12-12 | 2024-07-11 | ブリストル－マイヤーズ スクイブ カンパニー | トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途 |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| CN109705219B (zh) * | 2019-01-08 | 2020-11-13 | 上海霖科生物科技有限公司 | 与间皮素结合的单克隆抗体及其制备方法 |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| US20240377413A1 (en) | 2019-09-16 | 2024-11-14 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| CN110698562B (zh) * | 2019-10-31 | 2022-10-25 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
| EP4069731A4 (en) | 2019-12-03 | 2024-05-29 | Alamar Biosciences, Inc. | Nucleic acid linked immune-sandwich assay (nulisa) |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| JP2023507323A (ja) | 2019-12-20 | 2023-02-22 | アムジエン・インコーポレーテツド | 固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト |
| CN113698492B (zh) * | 2020-05-22 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
| CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| WO2022177913A1 (en) * | 2021-02-16 | 2022-08-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to mesothelin polypeptides |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| KR102860436B1 (ko) * | 2021-06-30 | 2025-09-19 | (주)이노베이션바이오 | 메소텔린 특이적 항체 및 이의 용도 |
| TW202321296A (zh) | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
| JP2025501452A (ja) * | 2021-12-10 | 2025-01-22 | メルク・シャープ・アンド・ドーム・エルエルシー | ヒトメソテリン結合物質 |
| WO2023115528A1 (en) * | 2021-12-24 | 2023-06-29 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against mesothelin and uses thereof |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| CN119562830A (zh) | 2022-06-02 | 2025-03-04 | 百时美施贵宝公司 | 抗体组合物及其使用方法 |
| EP4720059A1 (en) | 2023-05-24 | 2026-04-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025188694A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Tricyclic tlr7 agonists and uses thereof |
| WO2025188693A1 (en) | 2024-03-05 | 2025-09-12 | Bristol-Myers Squibb Company | Bicyclic tlr7 agonists and uses thereof |
| WO2025247171A1 (en) * | 2024-05-27 | 2025-12-04 | Harbour Antibodies Bv | Anti-mesothelin antibodies |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
| US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
| US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
| US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| KR100208957B1 (ko) | 1990-04-25 | 1999-07-15 | 로렌스 티. 마이젠헬더 | 신규한 cc-1065 유사체 |
| CA2093928C (en) | 1990-10-12 | 2000-02-29 | Mark C. Willingham | Monoclonal antibodies for detection and treatment of cancer |
| JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Ｄｃ−８９誘導体の臭化水素酸塩 |
| JP3328341B2 (ja) | 1991-12-27 | 2002-09-24 | 中外製薬株式会社 | 新規な巨核球増幅因子 |
| IL107366A (en) | 1992-10-23 | 2003-03-12 | Chugai Pharmaceutical Co Ltd | Genes coding for megakaryocyte potentiator |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5641780A (en) | 1994-04-22 | 1997-06-24 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolo-indole derivatives |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
| AU3532895A (en) | 1994-09-30 | 1996-04-26 | Kyowa Hakko Kogyo Co. Ltd. | Antitumor agent |
| CA2230759C (en) * | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| US7375183B1 (en) | 1996-01-05 | 2008-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof |
| JP2000505787A (ja) | 1996-01-05 | 2000-05-16 | アメリカ合衆国 | 中皮抗原及びそれを標的化するための方法及びキット |
| ES2255194T3 (es) * | 1997-12-01 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos, que incluyen moleculas fv, e inmunoconjugados que presentan una afinidad de enlace elevada para la mesotelina y metodos para su utilizacion. |
| US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| AU3007200A (en) | 1999-02-26 | 2000-09-14 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| DE60039510D1 (de) | 1999-05-27 | 2008-08-28 | Us Gov Health & Human Serv | Immunokonjugate mit hoher bindungsaffinität |
| US7288390B2 (en) * | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| US7125663B2 (en) | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| WO2002102235A2 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR100988949B1 (ko) * | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| ES2349777T3 (es) * | 2003-01-22 | 2011-01-11 | Glycart Biotechnology Ag | Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora. |
| CZ308720B6 (cs) | 2003-01-22 | 2021-03-24 | Roche Glycart Ag | Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| WO2005014652A1 (en) | 2003-08-05 | 2005-02-17 | Morphotek, Inc. | A variant cell surface molecule associated with cancer |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| KR101374514B1 (ko) * | 2003-12-10 | 2014-03-13 | 메다렉스, 인코포레이티드 | Ｉｐ―１０ 항체 및 그의 용도 |
| US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
| US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| US7517903B2 (en) | 2004-05-19 | 2009-04-14 | Medarex, Inc. | Cytotoxic compounds and conjugates |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| US7947839B2 (en) | 2004-12-01 | 2011-05-24 | Genentech, Inc. | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use |
| EP2322560B1 (en) * | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| WO2006124641A2 (en) * | 2005-05-12 | 2006-11-23 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Anti-mesothelin antibodies useful for immunological assays |
| AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
| CN101365679B (zh) | 2005-10-26 | 2012-11-14 | 梅达莱克斯公司 | 制备cc-1065类似物的方法和化合物 |
| WO2007100385A2 (en) | 2005-10-31 | 2007-09-07 | Genentech, Inc. | Macrocyclic depsipeptide antibody-drug conjugates and methods |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| US8940784B2 (en) | 2006-02-02 | 2015-01-27 | Syntarga B.V. | Water-soluble CC-1065 analogs and their conjugates |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | 梅達雷克斯有限責任公司 | 化學鏈接劑與可裂解基質以及其之綴合物 |
| CN101012280A (zh) * | 2007-02-07 | 2007-08-08 | 吴小华 | 抗人可溶性间皮素相关蛋白单克隆抗体的制备方法 |
| KR20090122439A (ko) | 2007-02-21 | 2009-11-30 | 메다렉스, 인코포레이티드 | 단일 아미노산을 갖는 화학적 링커 및 이의 접합체 |
| SI2195017T1 (sl) * | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
| HUE027358T2 (en) * | 2007-11-26 | 2016-09-28 | Bayer Ip Gmbh | Anti-mesothelin antibodies and their applications |
-
2008
- 2008-09-29 SI SI200831341T patent/SI2195017T1/sl unknown
- 2008-09-29 AU AU2008308956A patent/AU2008308956B2/en not_active Ceased
- 2008-09-29 EA EA201070412A patent/EA018396B1/ru not_active IP Right Cessation
- 2008-09-29 PL PL08836490T patent/PL2195017T3/pl unknown
- 2008-09-29 US US12/681,215 patent/US8268970B2/en active Active
- 2008-09-29 DK DK08836490.6T patent/DK2195017T3/en active
- 2008-09-29 NZ NZ584633A patent/NZ584633A/en not_active IP Right Cessation
- 2008-09-29 KR KR1020107009426A patent/KR101554753B1/ko not_active Expired - Fee Related
- 2008-09-29 ES ES08836490.6T patent/ES2526355T3/es active Active
- 2008-09-29 HR HRP20150074AT patent/HRP20150074T1/hr unknown
- 2008-09-29 PT PT88364906T patent/PT2195017E/pt unknown
- 2008-09-29 KR KR1020157008793A patent/KR101554848B1/ko not_active Expired - Fee Related
- 2008-09-29 CA CA2700860A patent/CA2700860C/en not_active Expired - Fee Related
- 2008-09-29 JP JP2010528054A patent/JP5535074B2/ja not_active Expired - Fee Related
- 2008-09-29 MX MX2010003581A patent/MX2010003581A/es active IP Right Grant
- 2008-09-29 RS RS20150044A patent/RS53760B1/sr unknown
- 2008-09-29 WO PCT/US2008/078123 patent/WO2009045957A1/en not_active Ceased
- 2008-09-29 CN CN200880110024.5A patent/CN101951946B/zh not_active Expired - Fee Related
- 2008-09-29 EP EP08836490.6A patent/EP2195017B1/en active Active
- 2008-09-29 BR BRPI0816014A patent/BRPI0816014A8/pt not_active Application Discontinuation
- 2008-09-30 CL CL2008002923A patent/CL2008002923A1/es unknown
- 2008-09-30 AR ARP080104267A patent/AR068590A1/es unknown
- 2008-10-01 TW TW097137770A patent/TWI446922B/zh not_active IP Right Cessation
-
2010
- 2010-03-18 IL IL204615A patent/IL204615A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02313A patent/ZA201002313B/en unknown
- 2010-04-27 CO CO10049719A patent/CO6300960A2/es active IP Right Grant
-
2012
- 2012-08-16 US US13/587,644 patent/US8425904B2/en active Active
- 2012-08-16 US US13/587,572 patent/US8383779B2/en active Active
- 2012-08-16 US US13/587,500 patent/US8399623B2/en active Active
-
2013
- 2013-03-14 US US13/827,946 patent/US20130190481A1/en not_active Abandoned
-
2015
- 2015-01-21 CY CY20151100062T patent/CY1116036T1/el unknown
- 2015-12-28 IL IL243375A patent/IL243375B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| BR112021011014A2 (pt) | Anticorpos anti-claudina e usos destes | |
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| TW201920078A (zh) | 抗體－藥物結合物之新穎製造方法 | |
| TWI874262B (zh) | 抗her3抗體-藥物結合物之用途 | |
| JP7473474B2 (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| JPWO2018066626A1 (ja) | 抗ｈｅｒ２抗体−薬物コンジュゲート投与による耐性癌の治療 | |
| JPWO2021177438A5 (enExample) | ||
| CN120501882A (zh) | 通过施用抗her2抗体-药物缀合物治疗her2突变的癌 | |
| JP2026504636A5 (enExample) | ||
| WO2021252578A1 (en) | Anti-human neurotensin receptor 1 antibody and use thereof | |
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| EP4721766A1 (en) | Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| BR122024023391A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica | |
| CA3294003A1 (en) | Combination of anti-her3 antibody-drug conjugate and rasg12c inhibitor | |
| WO2024210162A1 (ja) | 抗ｍｕｃ１抗体－薬物コンジュゲート投与による薬剤低感受性がんの治療方法 | |
| HK40130006A (zh) | 通过施用抗her2抗体-药物缀合物治疗her2突变的癌 | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| EA050611B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| BR122023026672A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| BR122023026675A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| BR122023026673A2 (pt) | Uso de um conjugado de anticorpo-fármaco | |
| EA046932B1 (ru) | Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство |